Type of Study:
Vaccine
Study Length:
~18 months
Target Age/Sex:
Male or Female Infants 42-98 days old
Benefits:
Participants will receive at no cost: Study product an standard of care vaccines, study visits, and study specific procedures. Participants may also receive compensation for their time and travel
Staus: Enrolling
Description:
A vaccine trial comparing Prevnar 20 to Prevnar 20+5 which includes 5 addition strains of pneumonia following the CDC guidelines for vaccination schedule.